Bengaluru, Apr 26 (PTI)Biocon Biologics Ltd.,a subsidiary ofBengaluru-headquartered Biocon Ltd., has announced thatAbevmy 100 & 400 mg,abiosimilar of Bevacizumab co-developed with Viatris Inc., hasreceived marketing authorisation approvalfrom theEuropean Commission.

The nod came following the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, it said.

Abevmy 100 & 400 mg is approved for the treatment inmetastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, the company said.

The centralised marketing authorisation granted by the EC is valid in all EU Member States as well as in the European Economic Area countries Iceland, Liechtenstein and Norway, it was stated.

"The European Commission's approval of our biosimilar Bevacizumab will enable us to offer this biologic therapy to cancer patients in the EU along with our partner Viatris," a Biocon Biologics spokesperson said.

The addition of biosimilar Bevacizumab will strengthen the company's portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim, the spokesperson said.PTI RS SS

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)